ArticleCureus2026
Predictors of Clinical Outcome in Primary Progressive and Relapsed Wilms Tumor in a Resource-Limited Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate survival outcomes and identify prognostic factors associated with relapse or treatment-refractory primary progressive Wilms tumor in a resource-limited South Asian setting. STUDY DESIGN AND
settingThis is a retrospective cohort study conducted at a single tertiary-care pediatric oncology center in Pakistan. MATERIALS AND
methodsClinical charts of patients aged under 18 years were retrospectively examined and included. Patients who had been diagnosed with relapsed or treatment-refractory primary progressive Wilms tumor during the period between January 2010 and December 2023 were included in the study. The occurrence of disease following full remission after usual therapy was termed relapse, whereas the absence of radiologic or symptomatic response to the first chemotherapy was termed primary progressive disease. The Kaplan-Meier was used to estimate overall survival and event-free survival.
resultsAmong 452 children treated for Wilms tumor, 58 (13%) developed relapse or disease progression. Five-year overall survival was 43% (95% confidence interval: 29-57%). Event-free survival (survival without relapse, progression, death, or abandonment) fell to 28% at one year and 20% at two years. At the time of diagnosis, stage 4 disease had a worse survival rate than stage 3 (24% vs 49%).
conclusionsPresentation at an advanced stage of the disease and the inability to achieve first remission are strong predictors of poor survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.